What is the intrinsic value of JAZZ?
As of 2026-09-29, the Intrinsic Value of Jazz Pharmaceuticals PLC (JAZZ) is
74.88 USD. This JAZZ valuation is based on the model Peter Lynch Fair Value.
With the current market price of 238.28 USD, the upside of Jazz Pharmaceuticals PLC is
-68.58%.
Is JAZZ undervalued or overvalued?
Based on its market price of 238.28 USD and our intrinsic valuation, Jazz Pharmaceuticals PLC (JAZZ) is overvalued by 68.58%.
74.88 USD
Intrinsic Value
JAZZ Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
(1,132.91) - (119.37) |
(180.54) |
-175.8% |
| DCF (Growth 10y) |
(131.10) - (1,229.20) |
(197.68) |
-183.0% |
| DCF (EBITDA 5y) |
(74.43) - (88.67) |
(1,234.50) |
-123450.0% |
| DCF (EBITDA 10y) |
(83.38) - (98.55) |
(1,234.50) |
-123450.0% |
| Fair Value |
74.88 - 74.88 |
74.88 |
-68.58% |
| P/E |
214.15 - 322.57 |
254.58 |
6.8% |
| EV/EBITDA |
218.47 - 386.29 |
284.87 |
19.6% |
| EPV |
232.86 - 349.54 |
291.20 |
22.2% |
| DDM - Stable |
202.31 - 1,447.91 |
825.11 |
246.3% |
| DDM - Multi |
(81.37) - (462.61) |
(139.40) |
-158.5% |
JAZZ Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
14,968.75 |
| Beta |
0.06 |
| Outstanding shares (mil) |
62.82 |
| Enterprise Value (mil) |
17,700.35 |
| Market risk premium |
4.60% |
| Cost of Equity |
6.86% |
| Cost of Debt |
5.28% |
| WACC |
5.87% |